Background: Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression.

Methods: The present study aimed to examine the effect of treatment with fluoxetine or mirtazapine, given separately or jointly with risperidone, on active behavior and plasma corticosterone level in male Wistar rats subjected to the forced swim test (FST).

Results: The obtained results showed that fluoxetine (5 mg/kg), mirtazapine (5 and 10 mg/kg) or risperidone (0.05 and 0.1 mg/kg) did not change the active behavior of rats in the FST. However, co-treatment with fluoxetine (10 mg/kg) and risperidone (0.1 mg/kg) induced an antidepressant-like effect in that test because it significantly increased the swimming time and decreased the immobility time, while combined treatment with mirtazapine at 5 and 10 mg/kg and risperidone at 0.05 and 0.1 mg/kg evoked a significant increase in the swimming time and also climbing, and decreased the immobility time. WAY 100635 (a 5-HT(1A) receptor antagonist) at a dose of 0.1 mg/kg inhibited the antidepressant-like effect induced by co-administration of fluoxetine or mirtazapine and risperidone. Active behavior in that test did not reflect an increase in general activity, since combined treatment with fluoxetine or mirtazapine and risperidone failed to enhance the exploratory activity of rats. Co-treatment with fluoxetine or mirtazapine and risperidone did not reduce the stress-induced increase in plasma corticosterone concentration in animals subjected to the FST.

Conclusion: The obtained results indicate that risperidone applied in a low dose enhances the antidepressant-like activity of fluoxetine and mirtazapine in the FST (but does not normalize the stress-induced increase in corticosterone level in these rats), and that 5-HT(1A) receptors may play some role in these effects.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1734-1140(12)70936-2DOI Listing

Publication Analysis

Top Keywords

fluoxetine mirtazapine
24
mirtazapine risperidone
16
co-treatment fluoxetine
12
risperidone active
12
plasma corticosterone
12
active behavior
12
mg/kg risperidone
12
risperidone
10
mirtazapine
8
corticosterone concentration
8

Similar Publications

Purpose: This study investigates the potential association between commonly prescribed psychotropic medications, such as Atypical Antipsychotics (AAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), and congenital anomalies in newborns. The analysis uses data from the Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods: Spontaneously reported cases of congenital anomalies in newborns (under 28 days old) were extracted from the FAERS database, covering January 2004 to June 2023.

View Article and Find Full Text PDF

Background: Antidepressants' effects are established in randomised controlled trials (RCTs), but not in the real world.

Aims: To investigate real-world comparative effects of antidepressants for depression and compare them with RCTs.

Method: We performed a cohort study based on the QResearch database.

View Article and Find Full Text PDF

Background: The objective is to compare the risk of developing type 2 diabetes (T2D) within a year in patients prescribed various antidepressants (ADs) and those prescribed fluoxetine as a control group.

Methods: This study used standardized data from the Health Insurance Review and Assessment Service claims database (n=1,456,489). Patients aged ≥10 years with no previous use of ADs and no history of diabetes mellitus, regardless of whether they were diagnosed with any depressive disorder, were eligible for this study.

View Article and Find Full Text PDF
Article Synopsis
  • Depression is a widespread mental illness affecting nearly 30% of adolescents globally, and this study focuses on the prevalence and types of antidepressant prescriptions among diagnosed adolescents in Germany.
  • A cohort of 6,338 adolescents aged 13-17 was analyzed, revealing that 61% were prescribed antidepressants, with prescription rates increasing with age; Fluoxetine was the most commonly prescribed medication.
  • Factors such as age, severity of depression, and co-existing conditions like obsessive-compulsive disorder and eating disorders significantly influenced antidepressant prescriptions in this demographic.
View Article and Find Full Text PDF

MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients.

J Pharm Biomed Anal

January 2025

The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou 510000, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou 510000, China. Electronic address:

Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!